MARKET

ORMP

ORMP

Oramed
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.01
-0.07
-1.38%
Closed 16:00 01/27 EST
OPEN
4.990
PREV CLOSE
5.08
HIGH
5.23
LOW
4.920
VOLUME
62.91K
TURNOVER
--
52 WEEK HIGH
6.05
52 WEEK LOW
2.317
MARKET CAP
88.86M
P/E (TTM)
-6.9448
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ORMP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ORMP News

  • Oramed Elects Dr. Alexander Fleming to Scientific Advisory Board
  • PR Newswire.4d ago
  • Oramed Appoints Dr. Jay Skyler to Scientific Advisory Board
  • PR Newswire.6d ago
  • Oramed Pharmaceuticals Issues Letter to Shareholders
  • PR Newswire.01/09 12:00
  • Does Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Pay Compare Well With Peers?
  • Simply Wall St..01/07 16:38

More

Industry

Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.51%

Hot Stocks

Name
Price
%Change

About ORMP

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.
More

Webull offers Oramed Pharmaceuticals, Inc. (ORMP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.